← Back to Analyst Consensus 
ANIP Buy
ANI PHARMACEUTICALS INC
Current Price —
Implied Upside —
Analysts 15
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | initiate | — → Perform | — | 52% |
| Aug 10, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Aug 10, 2026 | Canaccord Genuity | maintain | Hold → Hold | — | 48% |
| Jul 17, 2026 | Canaccord Genuity | initiate | — → Hold | — | 48% |
| Jul 10, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Jan 16, 2026 | Guggenheim | maintain | Buy → Buy | $124 | 52% |
| Dec 9, 2025 | Barclays | initiate | — → Overweight | $100 | 53% |
| Nov 10, 2025 | Guggenheim | maintain | Buy → Buy | $115 | 52% |
| Oct 9, 2025 | Truist Securities | maintain | Hold → Hold | $90 | 54% |
| Sep 24, 2025 | JP Morgan | maintain | Overweight → Overweight | $115 | 54% |
| Sep 17, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $121 | 44% |
| Sep 8, 2025 | Guggenheim | maintain | Buy → Buy | $114 | 52% |
| Aug 11, 2025 | Truist Securities | maintain | Hold → Hold | $77 | 54% |
| Aug 8, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $93 | 44% |
| Jul 10, 2025 | HC Wainwright & Co. | initiate | — → Buy | $84 | 44% |
| May 12, 2025 | Guggenheim | reiterate | Buy → Buy | $86 | 52% |
| Apr 21, 2025 | Truist Securities | maintain | Hold → Hold | $65 | 54% |
| Apr 11, 2025 | Guggenheim | reiterate | Buy → Buy | $86 | 52% |
| Mar 17, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $94 | 44% |
| Mar 14, 2025 | Jefferies | initiate | — → Buy | $80 | 52% |
| Mar 12, 2025 | JP Morgan | initiate | — → Overweight | $85 | 54% |
| Mar 5, 2025 | Guggenheim | maintain | Buy → Buy | $86 | 52% |
| Mar 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $94 | 44% |
| Dec 11, 2024 | Leerink Partners | initiate | — → Outperform | $80 | 51% |
| Nov 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $94 | 44% |
| Oct 22, 2024 | Truist Securities | maintain | Hold → Hold | $62 | 54% |
| Oct 11, 2024 | Piper Sandler | initiate | — → Overweight | $68 | 54% |
| Sep 18, 2024 | Raymond James | maintain | Outperform → Outperform | $83 | 54% |
| Sep 17, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $94 | 44% |
| Sep 11, 2024 | Truist Securities | downgrade | Buy → Hold | $60 | 54% |
| Aug 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $94 | 44% |
| Jun 26, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $94 | 44% |
| May 13, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $87 | 44% |
| Apr 23, 2024 | Guggenheim | reiterate | Buy → Buy | $77 | 52% |
| Mar 15, 2024 | Capital One | initiate | — → Overweight | $0 | 30% |
| Mar 5, 2024 | Guggenheim | maintain | Buy → Buy | $77 | 52% |
| Mar 4, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $83 | 44% |
| Mar 1, 2024 | Truist Securities | maintain | Buy → Buy | $80 | 54% |
| Feb 16, 2024 | Truist Securities | maintain | Buy → Buy | $72 | 54% |
| Oct 19, 2023 | Guggenheim | reiterate | Buy → Buy | $72 | 52% |
| Sep 13, 2023 | Guggenheim | reiterate | Buy → Buy | $72 | 52% |
| Aug 22, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $73 | 44% |
| Aug 21, 2023 | Truist Securities | reiterate | Buy → Buy | $70 | 54% |
| Aug 10, 2023 | Guggenheim | maintain | Buy → Buy | $72 | 52% |
| Jul 27, 2023 | Guggenheim | maintain | Buy → Buy | $62 | 52% |
| Jul 21, 2023 | Truist Securities | maintain | Buy → Buy | $60 | 54% |
| May 9, 2023 | Guggenheim | maintain | — → Buy | $59 | 52% |
| May 9, 2023 | Truist Securities | maintain | — → Buy | $52 | 54% |
| May 9, 2023 | Raymond James | maintain | — → Outperform | $49 | 54% |
| May 9, 2023 | HC Wainwright & Co. | maintain | — → Buy | $60 | 44% |
Price Target Trend
Jun 13, 2026 Latest: $105.78 Oct 25, 2026
EPS Estimates
+1y $10.13
Lo: $9.46 Hi: $10.47
9 analysts 0y $9.26
Lo: $9.17 Hi: $9.37
9 analysts 0q $2.18
Lo: $2.02 Hi: $2.33
9 analysts ▲1
+1q $2.82
Lo: $2.57 Hi: $2.97
9 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days